• The global meningococcal vaccines market size is anticipated to grow nearly 2X, expanding from USD 4.53 Bn in 2025 to USD 9.05 Bn by 2032, recording a CAGR of 10.4% throughout the forecast period.

Penmenvy combines the antigenic components of Bexsero (meningococcal Group B vaccine) and Menveo (meningococcal Groups A, C, Y, and W-135 oligosaccharide diphtheria CRM197 conjugate vaccine).

The CDC's Advisory Committee on Immunization Practices (ACIP) voted 14-0, with one abstention, on Wednesday to recommend that ...

This recommendation, if adopted, will allow for vaccination against serogroups A, B, C, W, and Y in fewer doses, could simplify meningococcal vaccination delivery and could improve immunization ...

The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in ...

Burlingame, CA, April 21, 2025 (GLOBE NEWSWIRE) -- Coherent Market Insights published a report, titled, the global meningococcal vaccines market size is estimated to grow from US$ 4.53 Billion in 2025 ...

The CDC's vaccine committee will convene for a two-day meeting this week to consider recommendations on vaccines, including ...

Kennedy Jr., a leading voice in the U.S. anti-vaccine movement. A Department of Health and Human ... Endorsement of a new ...

GSK plc announced that the US Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) has voted to recommend use of Penmenvy (Meningococcal Groups A, B, ...